OncoMatch/Clinical Trials/NCT07156136
Study of IMC-P115C in Advanced PRAME-Positive Cancers
Is NCT07156136 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies IMC-P115C for prame positive.
Treatment: IMC-P115C — Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: PRAME positive tumor testing
Meeting PRAME-positive tumor testing requirements
Required: HLA-A A*02:01-positive
HLA-A*02:01-positive
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify